Genmab reported positive Phase 3 data for Rina-S in second-line-plus platinum-resistant ovarian cancer, strengthening the potential commercial opportunity for the company's oncology pipeline. 🔹 Key Highlights 🧬 Positive Phase 3: Rina-S delivered positive Phase 3 data in 2L+ platinum-resistant ovarian cancer. 💰 Commercial Potential: The program is viewed as supporting approximately $2B in peak sales potential. 🚀 Launch Opportunity: Strong data could support rapid adoption following potential approval. 🧪 Head & Neck Cancer: Genmab also presented Phase 2 data from the Peto study in first-line head and neck cancer. 📊 Overall Survival: The study reported a median overall survival of approximately 28 months. ⚔️ Competitive Position: The data provides a potential competitive response to rival programs in the space. 📅 Upcoming Catalyst: Another Phase 3 readout expected in Q4 2026 could become an important catalyst. 💡 Why It Matters Positive late-stage data can materially reduce clinical uncertainty and improve the commercial outlook for oncology programs. Rina-S could become an important growth driver for Genmab if subsequent regulatory and launch milestones remain favorable. 🚀 ThinkSabio Start Your 7-Day FREE ThinkSabio Trial https://www.thinksabio.com/ ThinkSabio — Stocks Simplified